Author: Thuy Larsen

The MHRA (Medicines and Healthcare Products Regulatory Agency) UK has recently released the annual report of GCP inspection findings from 2016. A total of 10 commercial sponsors were inspected and there were 3 critical findings from 3 organisations. Critical finding 1: At the previous GCP inspection in 2013...

The FDA has maintained confidentiality agreements with European regulators (European Medicines Agency EMA) since 2003, which have allowed for the exchange of information as part of the respective regulatory and scientific process. However, the FDA and EMA could not, under these arrangements, share full inspection...

FDA and Office for Human Research Protections (OHRP) have relapsed final guidance that answers commonly asked questions on using electronic systems and processes to obtain informed consent. The guidance provides recommendations on the use of electronic system and processes to obtain informed consents such as graphics,...

The EU Clinical Trial Regulation will now come into application in 2019 instead of October 2018, as previously scheduled. EMA’s priority is to ensure that a high quality and functional system is delivered to the EU regulatory network and its stakeholders. Due to technical difficulties with the...

Albert Einstein:
Success = Work + Play
PharmaGCP:
Successful business = Knowledge + Quality
Get in touch with us
info@pharmagcp.com
We work closely with you and carry out research to understand your needs and wishes.